1. Home
  2. WATT vs AKTX Comparison

WATT vs AKTX Comparison

Compare WATT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Energous Corporation

WATT

Energous Corporation

HOLD

Current Price

$5.20

Market Cap

13.4M

Sector

Technology

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.27

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WATT
AKTX
Founded
2012
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
14.4M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
WATT
AKTX
Price
$5.20
$0.27
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
406.5K
1.6M
Earning Date
02-26-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,018,000.00
N/A
Revenue This Year
$509.64
N/A
Revenue Next Year
$210.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
600.23
N/A
52 Week Low
$3.62
$0.22
52 Week High
$22.20
$1.73

Technical Indicators

Market Signals
Indicator
WATT
AKTX
Relative Strength Index (RSI) 53.73 35.04
Support Level $4.80 $0.28
Resistance Level $8.20 $0.31
Average True Range (ATR) 0.69 0.03
MACD 0.21 0.01
Stochastic Oscillator 35.92 26.92

Price Performance

Historical Comparison
WATT
AKTX

About WATT Energous Corporation

Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: